Research graph
References from CD5-targeted LNP-mRNA generates CD19 CAR-T cells in the body to achieve lupus remission without clearing lymph nodes. Local targets link to admitted publications; unresolved targets remain external evidence.
Systemic lupus erythematosus
10.1056/nejmra1100359 · 2011 · External reference
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
2011 · External reference
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
2010 · External reference
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
2012 · External reference
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
2018 · External reference
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
2017 · External reference
Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy
2020 · External reference
CD19-targeted CAR T cells in refractory systemic lupus erythematosus
10.1056/nejmc2107725 · 2021 · External reference
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
2022 · External reference
CD19-targeted CAR T cells in refractory antisynthetase syndrome
2023 · External reference
Anti-CD19 CAR T cells for refractory myasthenia gravis
2023 · External reference
Global manufacturing of CAR T cell therapy
2017 · External reference
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
2022 · External reference
Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
2019 · External reference
Value and affordability of CAR T-cell therapy in the United States
2020 · External reference
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
2020 · External reference
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
2020 · External reference
Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering
2020 · External reference
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021 · External reference
Unresolved reference
2022 · External reference
CAR T cells produced in vivo to treat cardiac injury
2022 · External reference
Aberrant T cell signaling and subsets in systemic lupus erythematosus
10.3389/fimmu.2018.01088 · 2018 · External reference
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
2019 · External reference
CD19-targeted CAR T cells in refractory systemic lupus erythematosus
10.1056/nejmc2107725 · ExternalCitation · doi-reference
Systemic lupus erythematosus
10.1056/nejmra1100359 · ExternalCitation · doi-reference
Aberrant T cell signaling and subsets in systemic lupus erythematosus
10.3389/fimmu.2018.01088 · ExternalCitation · doi-reference
